Special items: Ovarian Cancer and Us blog best viewed in Firefox
▼
Tuesday, February 16, 2010
Mismatch repair status and outcomes after adjuvant therapy in patients with surgically staged endometrial cancer (Lynch Syndrome mutations)
OBJECTIVES: "To determine whether DNA mismatch repair (MMR) modifies the response to chemotherapy or radiotherapy in patients with endometrial cancer......
METHODS: Immunohistochemistry (IHC) for the DNA MMR proteins MLH1, MSH2, MSH6, and PMS2 was performed on a tissue microarray of specimens of primary endometrial cancer."
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.